Drug intelligence / Profile preview

TAVST-02

Development stage: Preclinical
Lead developer: Tikva Allocell
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

TAVST-02 is a chimeric antigen receptor T cell (CAR-T) therapy under preclinical development for the treatment of neoplasms. It was initially developed by Tikva Allocell Pte Ltd. The specific target, mechanism of action, and additional details about the construct or tumor type have not been disclosed in public sources as of June 2025. CAR-T therapies are engineered to recognize and attack cancer cells by targeting specific antigens on their surface.

Beyond the preview

Go deeper on TAVST-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAVST-02.

Explore the full profile